TY  - JOUR
AU  - Bailey, T S
AU  - Takács, R
AU  - Tinahones, F J
AU  - Rao, P V
AU  - Tsoukas, G M
AU  - Thomsen, A B
AU  - Kaltoft, M S
AU  - Maislos, M
PY  - 2016
DO  - 10.1111/dom.12736
UR  - http://hdl.handle.net/10668/10244
T2  - Diabetes, obesity & metabolism
AB  - To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in...
LA  - en
KW  - GLP-1 receptor agonist
KW  - liraglutide
KW  - sitagliptin
KW  - type 2 diabetes
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Asia
KW  - Blood Glucose
KW  - Body Weight
KW  - Diabetes Mellitus, Type 2
KW  - Double-Blind Method
KW  - Drug Substitution
KW  - Drug Therapy, Combination
KW  - Europe
KW  - Female
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hypoglycemia
KW  - Hypoglycemic Agents
KW  - Liraglutide
KW  - Male
KW  - Metformin
KW  - Middle Aged
KW  - Nausea
KW  - North America
KW  - Sitagliptin Phosphate
KW  - Treatment Outcome
TI  - Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
TY  - research article
VL  - 18
ER  -